Videos

FDA‑approved zongertinib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.

In the ARES trial, MaaT013 led to improvement in refractory lower GI chronic GVHD, a key unmet need in patients receiving hematopoietic cell transplant.

Dr. Alexander B. Olawaiye speaks on how the ROSELLA trial shows relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer.

An ongoing trial could establish new standard of care for chronic graft-vs-host disease.

Limited lung cancer tissue? Pair liquid biopsy with NGS to spot actionable mutations fast and choose targeted therapy without delaying care.

Explore first-line therapy for HER2-mutated advanced NSCLC in an older patient, covering biomarker testing, liquid biopsy timing, and tailored HER2-targeted options.

Persistent itch can signal serious immunotherapy skin toxicity; learn triage tips, risk factors, and when to refer to dermatology fast.

Amandeep Salhotra, MD, discusses a retrospective observational analysis comparing Orca-T to standard graft with posttransplant cyclophosphamide.

Dr. Doroshow addresses the critical gap that shaped Sandra's treatment trajectory: incomplete upfront molecular testing in community oncology.

Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus lazertinib, and osimertinib plus chemotherapy against Mrs. Chen's stated goals of maximizing long-term survival, minimizing clinic visits, and staying chemo-free if possible.

Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with progressive shortness of breath and about 10 pounds of unintentional weight loss over 2 months.

Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung cancer (NSCLC), adenocarcinoma subtype.

The ACCESS study of post-transplant cyclophosphamide in stem cell transplant showed that even 6/8 and 5/8 HLA matches can be considered as donors.

Explore why high‑risk CLL often favors continuous BTK inhibitors over time‑limited venetoclax, balancing efficacy with clinic-visit burden.

Long-term zanubrutinib keeps atrial fibrillation risk low while manageable hypertension, neutropenia and infections emerge with continued therapy.

High‑risk del17p CLL patients on single‑agent zanubrutinib show durable progression‑free survival, rivaling outcomes in standard‑risk groups.

High-risk DEL17p CLL patients show durable progression-free survival on single-agent zanubrutinib, matching outcomes seen in standard-risk groups.

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk del17p/TP53 patients.

Longer follow-up of patients receiving a modern prophylactic regimen shows positive outcomes for preventing chronic GVHD and relapse after stem cell transplant.

New FDA-approved zongepanib boosts responses in HER2-mutant lung cancer, delivering durable control with fewer side effects than standard chemo.

Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new HER2-targeted treatments.

In this segment on advanced renal cell carcinoma, Dr. Wulff explores how the potential incorporation of belzutifan-based regimens into NCCN recommendations could influence future treatment sequencing.

In this segment on advanced renal cell carcinoma, Dr. McGregor introduces emerging data from the LITESPARK-011 study evaluating belzutifan in combination with lenvatinib compared with cabozantinib in previously treated patients.

Rusfertide may reduce phlebotomy needs in polycythemia vera, offering a convenient weekly self-injection option that could improve patient quality of life.

A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast cancer trials beyond binary pCR.

Enrolling pediatric patients and identifying biomarkers for response are the priorities for research of ozekibart in Ewing sarcoma.

ZUMA-2 cohort 3 shows brexu-cel CAR T delivers 91% responses in mantle cell lymphoma, with manageable CRS/ICANS, driving full FDA approval.

Dr Richard Goldberg discusses how outdated FDA metrics may delay immunotherapy approvals for oncology agents.

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose testing and expanded eligibility, enabling full FDA approval.

Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient groups.